AMAS and survival data

Both monitoring data (ref.4) and a retrospective survival study of 511 cancer patients (ref.6) have shown that the AMAS test may be useful in indicating disease progression and prognosis. Thus in known cancer patients,when the immune response is good as evidenced by high antibody levels, the prognosis is good; and when the antibody level falls, the prognosis is poor.

Anti-Malignin Antibody is the first general cancer antibody found to relate to patient survival. The test therefore may be useful as an adjunct to standard (sometimes less accurate) staging information such as the spread of malignancy beyond the capsule of the primary or gan and the presence of metastases in lymph nodes, or general symptoms such as anemia, weight loss and fatigue.